DCAF4L2: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: DCAF4L2

NCBI ID: G138009

DCAF4L2

DCAF4L2: A Potential Drug Target for Cancer and Neurodegenerative Diseases

DCAF4L2 (DDB1 and CUL4 associated factor 4 like 2) is a protein that is expressed in various tissues and cells throughout the body. Its primary function is to promote the growth and development of tissues, particularly the brain and spinal cord. It is a key regulator of the Wnt signaling pathway, a critical pathway that regulates cell growth, differentiation, and survival.

DCAF4L2 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its role in these conditions makes it an attractive target for researchers to study and develop new treatments.

DCAF4L2 and the Wnt Signaling Pathway

The Wnt signaling pathway is a critical regulatory pathway that regulates the development and maintenance of tissues during embryonic development. It is a complex signaling pathway that involves the interaction between various proteins, including DCAF4L2.

DCAF4L2 is a key regulator of the Wnt signaling pathway. It is part of a protein complex that is involved in the regulation of the Wnt signaling pathway. This protein plays a critical role in the negative regulation of the pathway, ensuring that it is activated in a specific and controlled manner.

DCAF4L2 is a critical regulator of the Wnt signaling pathway because it regulates the activity of the transcription factor, SMAD. SMAD is a key regulator of the Wnt signaling pathway, and it plays a critical role in the regulation of stem cell proliferation and differentiation.

DCAF4L2 is also involved in the regulation of the cytoskeleton, which is a critical component of the Wnt signaling pathway. Its role in this pathway is to ensure the proper alignment and organization of the cytoskeleton, which is necessary for the proper functioning of the pathway.

DCAF4L2 and Cancer

DCAF4L2 has been identified as a potential drug target or biomarker for cancer. Its role in the regulation of the Wnt signaling pathway makes it an attractive target for cancer therapies that target this pathway.

Studies have shown that DCAF4L2 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It is also involved in the regulation of the angiogenesis, which is the process by which tumors grow and expand.

DCAF4L2 is a good candidate for anti-cancer therapies because it is involved in the regulation of a critical pathway that is involved in cancer development. It is also a protein that is expressed in various types of cancer, making it a potentially useful biomarker for cancer diagnostics and therapies.

DCAF4L2 and Neurodegenerative Diseases

DCAF4L2 has also been identified as a potential drug target or biomarker for neurodegenerative diseases. The neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells.

DCAF4L2 is involved in the regulation of the Wnt signaling pathway, which is critical for the development and maintenance of neural tissues. Its role in this pathway is to ensure that the neural tissues are properly formed and that they function properly.

Studies have shown that DCAF4L2 is involved in the regulation of neurodegenerative diseases. It is expressed in the brains of individuals with Alzheimer's disease and is involved in the development of neurofibrillary tangles and neuroglial cells.

DCAF4L2 is also a good candidate for neurodegenerative disease therapies because it is involved in the regulation of a critical pathway that is involved in the development and maintenance of neural tissues. It is also a protein that is expressed in various types of neurodegenerative diseases, making it a potentially useful biomarker for

Protein Name: DDB1 And CUL4 Associated Factor 4 Like 2

The "DCAF4L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF4L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets